Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of AC-1202 vs AC-SD-01 in Healthy Males
NCT03063645Phase 1Completed
- Sponsor
- Cerecin
- Start
- Mar 2017
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tricaprilin in Alzheimer's disease (AD) (3 arms), sponsored by Cerecin. Primary endpoints: Total Ketones Area Under the Curve from time 0 to last measurable concentration, Total Ketones Area Under the Curve from time 0 to infinity and 7 more. Started Mar 2017; status: completed.
02
Drugs
tricaprilin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03063645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03063645.